Survival for adolescent and young adult leukemia survivors remained below the general population at up to 30 years of follow-up.
The risk of dying from a subsequent primary cancer remained significantly elevated for 20 years or more for some patients.
Younger patients with cancer are “a high-risk population for poor outcomes from COVID-19,” according to researchers.
The addition of daratumumab resulted in a 41% reduction in the risk of disease progression or death.
Adding elotuzumab to lenalidomide and dexamethasone did not improve any efficacy outcomes.
Researchers sought to determine whether there were long-term benefits for patients with hematologic malignancies treated with allo-HSCT and omidubicel.
Nearly 70% of patients had at least 1 potentially actionable therapeutic target.
Progression-free and overall survival is similar for minority and nonminority patients receiving CAR T-cell therapy for non-Hodgkin lymphoma.
There was no significant difference in transplant-related mortality or overall survival.
Researchers sought to determine the reasons for a disparity in patients who receive CAR-T therapy.
The approach resulted in low rates of graft failure, viral infections, and relapse.
There was no survival improvement with idasanutlin in the overall population or among patients with wild-type TP53.
Researchers sought to determine the costs of care and health resource use of patients with hematologic malignancies undergoing allo-HCT.
Researchers observed persistent anti-RBD antibodies at 6 months after the second dose of an mRNA COVID-19 vaccine and a 20-fold increase in anti-RBD antibodies after the third dose.
The risk of neurologic adverse events was 41% lower in patients treated with immune checkpoint inhibitors than in patients who received another drug regimen or a placebo.
Among patients with Abn1q, those who received bortezomib-based maintenance had significantly worse progression-free survival and overall survival.
Growing evidence suggests that patients with cancer have better responses to the Moderna COVID-19 vaccine than to the Pfizer-BioNTech vaccine.
Most cancer patients should receive 3 primary doses of an mRNA COVID-19 vaccine and 2 booster doses, according to NCCN.
The 1-year progression-free survival rate was 45%, and the 1-year overall survival rate was 59%.
Researchers sought to determine gene regulation patterns that may help predict response to CAR-T therapy in patients with acute lymphoblastic leukemia.